HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David M Pariser Selected Research

glycopyrronium tosylate

1/2021Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
5/2020Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
8/2019A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
2/2019Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
1/2019Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
1/2019Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David M Pariser Research Topics

Disease

26Psoriasis (Pustulosis Palmaris et Plantaris)
05/2022 - 04/2003
12Hyperhidrosis
01/2021 - 05/2007
11Acne Vulgaris
01/2022 - 08/2005
8Onychomycosis (Tinea Unguium)
07/2021 - 04/2013
6Actinic Keratosis
04/2022 - 02/2003
4Erythema
11/2018 - 11/2003
3Basal Cell Carcinoma (Rodent Ulcer)
10/2021 - 02/2006
2Atopic Dermatitis (Atopic Eczema)
06/2022 - 08/2005
2Infections
02/2018 - 06/2015
2Neoplasms (Cancer)
08/2012 - 11/2009
2Rosacea (Acne Rosacea)
02/2006 - 11/2003
1Asthma (Bronchial Asthma)
06/2022
1Allergic Rhinitis
06/2022
1Skin Neoplasms (Skin Cancer)
10/2021
1Melanoma (Melanoma, Malignant)
10/2021
1Bowen's Disease (Disease, Bowen)
10/2021
1Pruritus (Itching)
06/2020
1Vomiting
11/2019
1Diarrhea
11/2019
1Dizziness (Lightheadedness)
11/2019
1Headache (Headaches)
11/2019
1Nasopharyngitis
11/2019
1Nausea
11/2019
1Respiratory Tract Infections (Respiratory Tract Infection)
11/2019
1Sunburn
11/2019
1Phototoxic Dermatitis (Phototoxicity)
11/2019
1Body Weight (Weight, Body)
05/2016
1Psoriatic Arthritis
05/2016
1Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2016
1Hypotrichosis
07/2015
1Lichen Planus (Lichen Ruber Planus)
02/2013
1Wounds and Injuries (Trauma)
09/2011

Drug/Important Bio-Agent (IBA)

6Cholinergic Antagonists (Anticholinergics)IBA
01/2021 - 02/2017
6glycopyrronium tosylateIBA
01/2021 - 01/2019
5Adrenal Cortex Hormones (Corticosteroids)IBA
06/2022 - 03/2017
51-phenyl-3,3-dimethyltriazene (PDT)IBA
10/2021 - 02/2003
5halobetasol (ulobetasol)FDA LinkGeneric
01/2019 - 03/2017
5tazarotene (Tazorac)FDA Link
01/2019 - 03/2017
4Adapalene (Differin)FDA LinkGeneric
01/2022 - 08/2005
3Benzoyl PeroxideFDA LinkGeneric
01/2022 - 09/2007
3Immunoglobulin A (IgA)IBA
07/2018 - 12/2016
3tavaboroleIBA
02/2018 - 06/2015
3efinaconazoleIBA
03/2016 - 04/2013
3efalizumab (Raptiva)FDA Link
01/2008 - 12/2005
2Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 11/2019
2clindamycin phosphate (Clindets)FDA LinkGeneric
01/2022 - 09/2014
2SolutionsIBA
07/2021 - 04/2013
2Infliximab (Remicade)FDA Link
01/2021 - 01/2008
2Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric
01/2021 - 08/2019
2Tretinoin (Retinoic Acid)FDA LinkGeneric
12/2020 - 10/2018
2apremilastIBA
07/2016 - 02/2013
2Etanercept (Enbrel)FDA Link
02/2016 - 08/2012
2Type A Botulinum Toxins (Botox)FDA Link
09/2015 - 05/2007
2Ciclopirox (Loprox)FDA LinkGeneric
06/2015 - 09/2003
2AntiperspirantsIBA
10/2014 - 10/2014
2Ointments (Pastes)IBA
04/2007 - 08/2005
1dupilumabIBA
06/2022
1tildrakizumabIBA
05/2022
1RetinoidsIBA
01/2022
1Drug CombinationsIBA
01/2022
1GelsIBA
01/2022
1AcidsIBA
10/2021
1Terbinafine (Lamisil)FDA LinkGeneric
07/2021
1Ustekinumab (CNTO 1275)FDA Link
01/2021
1PF-06700841IBA
12/2020
1Neurokinin-1 Receptor AntagonistsIBA
06/2020
1serlopitantIBA
06/2020
1secukinumabIBA
12/2019
1EnzymesIBA
12/2019
1Midazolam (Versed)FDA LinkGeneric
12/2019
1Interleukin-17 (Interleukin 17)IBA
12/2019
1Cytochrome P-450 CYP3AIBA
12/2019
1Tetracycline (Achromycin)FDA LinkGeneric
11/2019
1sarecyclineIBA
11/2019
1Therapeutic UsesIBA
07/2018
13-ingenyl angelateIBA
05/2017
1THVD-102IBA
02/2017
1Pilocarpine (Ocusert)FDA LinkGeneric
02/2017
1oxybutynin (Tavor)FDA LinkGeneric
02/2017
1Muscarinic AntagonistsIBA
02/2017
1Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
07/2016
1Janus Kinase InhibitorsIBA
05/2016
1tofacitinibIBA
05/2016
1Aminolevulinic Acid (Levulan)FDA Link
03/2016
1Pharmaceutical PreparationsIBA
03/2016
1Ophthalmic Solutions (Eye Drops)IBA
07/2015
1Bimatoprost (Lumigan)FDA Link
07/2015
1Antifungal AgentsIBA
06/2015
1AzolesIBA
06/2015
1BoronIBA
06/2015
1Botulinum Toxins (Botulinum Toxin)IBA
10/2014
1Clindamycin (Cleocin)FDA LinkGeneric
09/2014
1TriazolesIBA
04/2013
1Indicators and Reagents (Reagents)IBA
09/2011

Therapy/Procedure

19Therapeutics
06/2022 - 11/2003
4Photochemotherapy (Photodynamic Therapy)
10/2021 - 02/2003
3Biological Therapy
06/2022 - 04/2003
2Lasers (Laser)
03/2016 - 09/2015
2Injections
09/2015 - 10/2014
1Drug Therapy (Chemotherapy)
07/2015